People
The healthcare system is innovating to address the pain points the pandemic revealed. Specifically, it is becoming more proactive, preventative and personalized.
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO’s June 8 virtual session, “The Next Generation of Medicine: Cell Therapies, Gene Therapies and Beyond.”
The annual Biotechnology Innovation Organization meeting kicked off Monday with the proverbial passing of the baton from longtime head Jim Greenwood to Michelle McMurry-Heath, who was tapped to take over the organization last month.
Poll after poll shows that many Americans – 30% to 50% – are unwilling to be vaccinated against COVID-19 once a vaccine becomes available. Meanwhile, officials are banking on widespread vaccination to allow society to return to normal, without masks or social distancing.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.
Industry experts say a vaccine against the SARS-CoV-2 virus will either be ready this fall, at the end of the year or 18 months from now, depending on the vaccine and how they define “ready.”
PRESS RELEASES